agreement

  1. Lilly partners with AC Immune

    Eli Lilly to collaborate with AC Immune for the treatment of Alzheimer’s disease. Will it succeed and create a drug to cure Alzheimer's disease?
  2. United Therapeutics signs a deal with Arena

    United Therapeutics signs an agreement with Arena in a deal worth $1.2 billion. It will pay $800 million as upfront payment to Arena and $400 million as potential milestone payments. This is what exactly Arena investors have been looking for. This will be a win-win deal for both the companies...
  3. Allergan to pay $700 million to Teva

    Allergan agrees to pay $700 million to Teva in this quarter. Teva discloses this in an SEC filing.
  4. Thalomid - Confidential settlement with Lannett

    http://alph.st/b9f74234 Remember, Celgene settled a lawsuit for the fraudulent use of Thalomid in July 2017 for $280 million. Now Lannett is going to manufacture the generic version of Thalomid.
  5. Oncology collaboration

    Lilly signs a deal with Germany-based Curevac to strengthen its oncology division. http://alph.st/b72eaf5f
  6. Settles with Pfizer's subsidiary on Restasis patent

    Allergan reaches a settlement with InnoPharma, a subsidiary of Pfizer on Restasis patent. Out of the four contestants, Mylan, Teva and Akorn are still contesting the patents in the federal court. http://alph.st/b3437240
  7. Celgene and Acceleron amend agreement

    Celgene to receive royalties on global net sales in the pulmonary hypertension field.
  8. Allergan patent litigation

    Allergan reaches a settlement with Famy Care and it will grant Famy Care a license to market generic version of Restasis in U.S. in 2024.
  9. Cialis drug's "erectile dysfunction"

    Cialis, a drug that is used to treat impotence, was given for a free trial for the first time users in 2004. Now the patent for Cialis expires earlier than the previous date.